Apple Watch now approved to track Parkinson’s symptoms

Motion data from the watch will now be incorporated into Rune Labs’ Parkinson’s tracking app.

San Francisco neurology startup Rune Labs has gotten the green light from the FDA to use the Apple Watch to monitor and track Parkinson’s symptoms.

Rune’s app, StrivePD, combines self-reported experiences, brain imaging, and other clinical information with watch tracking to create a “data-driven approach to care management and clinical trial design for Parkinson’s,” the company said in a release.

The Apple Watch’s motion sensor can now be combined with that data from other sources, including brain monitoring devices from another partner, Medtronics, said Brian Pepin, founder and CEO of Rune. 

The startup announced their data collection partnership with Medtronics’ Percept​​ PC Deep Brain Stimulation device last year.

Incorporating the data from these various sources, Rune wants to help tailor patients’ treatments based on their Parkinson’s symptoms by generating reports patients can share with their doctors.

The Apple Watch’s motion sensor can now be combined with data from other sources to help track Parkinson’s symptoms.

Currently, doctors gather data on patient’s Parkinson’s symptoms during clinical visits, Pepin told Reuters. But symptoms can vary greatly over time, making visits more of a quick snapshot than an accurate portrait of the patient’s day-to-day condition.

“Being able to show my neurologist how my motor symptoms were fluctuating, thanks to StrivePD, was the impetus for me to get surgery for a deep brain stimulation device,” Aura Oslapas, who designed StrivePD, said in the release.

“When people with Parkinson’s are prescribed new medications, adjusting how much to take and when to take it until they find something that works can be a lengthy process,” said Oslapas, who has worked with Rune since the company acquired StrivePD in 2019.

While there are other devices that can track Parkinson’s symptoms, the ubiquity and convenience of the Apple Watch means “more people will have access to this life-changing technology,” Oslapas said.

FDA approval also allows clinicians to use the all-important insurance and Medicare billing codes when reviewing data from the device, STAT reported.

The StrivePD app creates a “data-driven approach to care management and clinical trial design for Parkinson’s,” developer Rune Labs said.

The software has been used by patients at UC San Francisco and Mount Sinai for half a year, TechCrunch reported.

Apple itself has already shown interest in Parkinson’s research, filing multiple patents and publishing a study in Science Translational Medicine demonstrating the smartwatch’s ability to track Parkinson’s symptoms in the real world.

“As we have seen in oncology, the introduction of large quantities of real-world data has the power to transform drug development and fundamentally change disease prognosis,” Pepin told TechCrunch.

“This clearance is a major step towards building a similar paradigm in neurology,”

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.

Related
In a future with brain-computer interfaces like Elon Musk’s Neuralink, we may need to rethink freedom of thought
In a future with more “mind reading,” thanks to computer-brain interfaces, we may need to rethink freedom of thought.
Personalized cancer vaccines are having a moment
Personalized cancer vaccines were a recurring theme at the annual meeting of the American Association for Cancer Research in 2024.
When an antibiotic fails: MIT scientists are using AI to target “sleeper” bacteria
Most antibiotics target metabolically active bacteria, but AI can help efficiently screen compounds that are lethal to dormant microbes.
OpenAI and Microsoft are reportedly planning a $100B supercomputer
Microsoft is reportedly planning to build a $100 billion data center and supercomputer, called “Stargate,” for OpenAI.
What’s next for COVID-19 drugs?
Paxlovid may have underperformed in a new trial, but other promising COVID-19 drugs are being authorized or in the works.
Up Next
Exit mobile version